ADC Therapeutics

ADC Therapeutics is developing antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. These proprietary PBD‑based ADCs are expected to provide a novel way to treat hematologic cancers and solid tumors, address significant unmet medical needs, and improve the lives of patients with cancer.